Earnings Call Summary | Prestige Consumer Healthcare(PBH.US) Q4 2024 Earnings Conference
Earnings Call Summary | Prestige Consumer Healthcare(PBH.US) Q4 2024 Earnings Conference
The following is a summary of the Prestige Consumer Healthcare Inc (PBH) Q4 2024 Earnings Call Transcript:
以下是Prestige Consumer Healthcare Inc（PBH）2024年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Prestige's Q4 performance fell short due to supply chain pressures and unfulfilled retailer orders but still generated a free cash flow of approximately $240 million for the full year.
The company achieved significant deleveraging with a year-end leverage ratio of 2.8, the lowest in its history.
Fiscal 2024 revenue and adjusted EPS remained unchanged compared to the previous year with Q4 experiencing a revenue drop of 2.9% organically.
For fiscal '25, the revenue is expected to range from $1.125 - $1.140 billion with an organic revenue growth of approximately 1%.
The company plans to initiate a multiyear $300 million share repurchase program with similar cash generation as '24.
由於供應鏈壓力和零售商訂單未完成，Prestige第四季度的業績表現不佳，但全年仍創造了約2.4億美元的自由現金流。
該公司實現了大幅去槓桿化，年終槓桿率爲2.8，爲歷史最低水平。
與上年相比，2024財年的收入和調整後的每股收益保持不變，第四季度收入有機下降了2.9％。
25財年的收入預計將在11.25億美元至11.40億美元之間，有機收入增長約1％。
該公司計劃啓動一項爲期多年的3億美元股票回購計劃，其現金產生與24年相似。
Business Progress:
業務進展：
In response to supply chain disruptions, the company is implanting a supply chain continuity strategy and has started commercial production of certain Monistat products.
The international segment witnessed a 10% organic revenue growth and contributes around 15% of the company's sales.
Despite current setbacks, Prestige anticipates strong consumption growth and expects e-commerce growth through strategic investment.
With supply chain issues for Clear Eyes brand and disruptions in Women's Health category, the company foresees recovery over the first half of fiscal '25.
The company Board approved a $300 million multiyear stock buyback plan aimed at offsetting share dilution, and they are considering disciplined M&A as a secondary priority.
爲了應對供應鏈中斷，該公司正在實施供應鏈連續性戰略，並已開始商業化生產某些Monistat產品。
國際分部實現了10％的有機收入增長，貢獻了公司銷售額的15％左右。
儘管目前遇到了挫折，但Prestige預計消費將強勁增長，並預計通過戰略投資實現電子商務增長。
由於Clear Eyes品牌的供應鏈問題以及女性健康類別的中斷，該公司預計25財年上半年將出現復甦。
公司董事會批准了一項旨在抵消股票稀釋的3億美元多年期股票回購計劃，他們正在考慮將嚴格的併購作爲次要優先事項。
More details: Prestige Consumer Healthcare IR
更多詳情： Prestige 消費者醫療保健
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。